Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07158749

Generalized and Domain-Specific Episodic Thinking for Smoking Cessation

Cigarette smoking remains common, particularly in rural areas, despite ample evidence that smoking causes cancer and respiratory disease. Successful smoking cessation yields the majority of its health benefits (e.g., avoidance of lung cancer) after years of sustained behavioral change; however, people who smoke cigarettes tend to show elevated rates of delay discounting (i.e., devaluation of delayed outcomes) and a bias for immediate gratification. The overall goal of this project is to develop different versions of an episodic future thinking intervention (i.e., visualization of the future) and test their feasibility and efficacy for smoking cessation in rural and urban populations.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fralin Biomedical Research Institute at VTC

Roanoke, Virginia, 24015, United States

Location contact

Jeffrey Stein, PhD

CONTACT

[email protected]

5405262124

About this study

Cigarette smoking causes more than a dozen cancers, including cancers of the head and neck, colon, bladder, and lung. Although quitting smoking drastically reduces the risk of cancer mortality, rates of cessation are low, particularly in rural areas and other communities. Current evidence-based treatments for smoking cessation have made progress, but substantial room for innovation remains and novel strategies are needed. Successful smoking cessation may be considered, in part, an intertemporal choice between continuing to smoke and achieving the delayed health benefits associated with quitting (e.g., avoidance of lung cancer). Thus, quitting requires one's behavior to be sufficiently motivated by future outcomes. Unfortunately, robust cross-sectional and longitudinal evidence indicates that people who smoke cigarettes show elevated delay discounting, or a bias for immediate gratification. Prior research shows that delay discounting predicts treatment failure and relapse in smoking cessation. These findings suggest that delay discounting often prevents successful quitting because the health benefits of cessation (e.g., avoiding cancer) are too delayed to motivate sustained behavioral change. Thus, delay discounting is a therapeutic target in smoking cessation, where interventions that increase valuation of future outcomes may facilitate quitting. Episodic future thinking (EFT) is one such scalable intervention that is designed to shift time perspective and reduce bias for immediate gratification by promoting vivid and frequent visualization of a broad range of personally significant future events (e.g., weddings, birthdays, spending time with loved ones). In laboratory studies, research has shown that this form of generalized EFT in cigarette smokers reduces delay discounting and motivation to smoke (i.e., cigarette consumption, craving, and valuation). Moreover, strong preliminary evidence suggests that cancer-related EFT, a novel form of the intervention that involves visualizing the future experience of smoking-related lung cancer, may be more efficacious for reducing urges to smoke than the generalized form. The proposed trial will adapt both forms of EFT (generalized and cancer-related) for clinical use in smoking cessation. Remote intervention delivery and outcomes assessment (breath carbon monoxide and number of cigarettes smoked per day) will be used to minimize clinical burden and increase intervention reach and access, including in rural populations who often lack access to evidence-based treatments for smoking cessation. In an eight-week proof-of-concept trial, participants will be prompted to engage in EFT or control episodic thinking multiple times per day and during acute craving episodes. Specific Aims 1 and 2 will examine the feasibility and efficacy, respectively, of generalized and cancer-related EFT to reduce smoking. An Exploratory Aim will investigate the potential moderating role of income, education, sex, and other characteristics (e.g., baseline delay discounting, cigarettes/day) in the effects of EFT on smoking outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • smoked cigarettes daily for the last 30 days;
  • salivary cotinine > 30 ng/mL, consistent with tobacco use;
  • plan to quit smoking in the next 30 days

Exclusion criteria

  • prior diagnosis with a smoking-related illness (e.g., respiratory disease);
  • past 30-day use any smoking cessation treatment;
  • anxiety or mood disorders; and
  • medical contraindications for use of nicotine replacement therapy (e.g. pregnancy).

Treatment and study plan

Episodic Future Thinking (EFT)

Behavioral

Participants will engage in EFT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.

Episodic Recent Thinking (ERT)

Behavioral

Participants will engage in ERT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.

Domain-specific episodic thinking

Behavioral

Content of the episodic thinking intervention will experiencing the symptoms of lung cancer during a broad range of personally meaningful, otherwise positive, events (e.g., social events, celebrations, spending times with friends and family).

Generalized episodic thinking

Behavioral

Content of the episodic thinking intervention will include a broad range of personally meaningful, positive, events (e.g., social events, celebrations, spending times with friends and family).

Primary outcomes

  1. Cigarettes smoked per day

    Time frame: From Week 0 to the end of treatment at 8 weeks

    A timeline followback questionnaire will be used to assess the number of cigarettes smoked per day. Lower values reflect better outcomes.

Secondary outcomes

  1. Other tobacco/nicotine product use per day

    Time frame: From Week 0 to the end of treatment at 8 weeks

    A timeline followback questionnaire will be used to assess the number of times participants use other tobacco/nicotine products per day (excluding cigarettes and nicotine patch). Lower values reflect better outcomes.

  2. 7-day point prevalence cigarette abstinence

    Time frame: Week 8

    A timeline followback questionnaire will be used to assess cigarette abstinence status (binary) over the final seven days of the intervention.

Other outcomes

  1. Nicotine patch adherence (feasibility outcome)

    Time frame: From Week 1 to the end of treatment at 8 weeks

    A timeline followback questionnaire will be used to assess frequency of use of the study-provided nicotine patches. Higher values reflect better adherence to nicotine replacement therapy.

  2. Depressive symptoms (feasibility outcome)

    Time frame: From Week 0 to the end of treatment at 8 weeks

    Depression symptoms over the last 2 weeks will be assessed using the Patient Health Questionnaire-8 (PHQ-8). Total scores on this scale range from 0 (no depressive symptoms) to 24 (severe depressive symptoms).

  3. Anxiety symptoms (feasibility outcome)

    Time frame: From Week 0 to the end of treatment at 8 weeks

    Anxiety symptoms over the last 2 weeks will be assessed using the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. Total scores on this scale range from 0 (no anxiety symptoms) to 21 (severe anxiety symptoms).

  4. Episodic thinking adherence (feasibility outcome)

    Time frame: From Week 1 to the end of treatment at 8 weeks

    Adherence to the episodic thinking interventions will be measured as the percentage of daily cue prompts that participants access.

  5. Perceived convenience (feasibility outcome)

    Time frame: From Week 1 to the end of treatment at 8 weeks

    Participants will evaluate perceived convenience of the intervention, both overall and its individual components, using visual analog scales with ratings ranging from 0 to 100. Higher ratings reflect greater convenience

  6. Perceived helpfulness (feasibility outcome)

    Time frame: From Week 1 to the end of treatment at 8 weeks

    Participants will evaluate perceived helpfulness of the intervention, both overall and its individual components, using visual analog scales with ratings ranging from 0 to 100. Higher ratings reflect greater helpfulness.

Study contacts

Contact information is provided by the study sponsor or research team.

Jeffrey Stein, PhD

CONTACT

[email protected]

15405262124

Sponsors and collaborators

Lead sponsor

Virginia Polytechnic Institute and State University

Other

Collaborators

  • National Cancer Institute (NCI)
  • Roswell Park Comprehensive Cancer Center

Registry information

Official study title

Generalized and Domain-Specific Episodic Thinking for Smoking Cessation: An 8-Week Pilot and Feasibility Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 8, 2025
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.